New therapies have raised Medicare treatment costs for metastatic prostate cancer
Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years—reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice.
Dec 20, 2022
0
0